X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ACTAVIS (US) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   ACTAVIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ACTAVIS
Dec-14
FRESENIUS KABI ONCO./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs17617,503-   
Low Rs7910,676-   
Sales per share (Unadj.) Rs37.73,151.8-  
Earnings per share (Unadj.) Rs5.1-393.3-  
Cash flow per share (Unadj.) Rs6.7289.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.56,836.1-  
Shares outstanding (eoy) m158.23265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.5 75.5%   
Avg P/E ratio x25.0-35.8 -69.7%  
P/CF ratio (eoy) x18.948.7 38.8%  
Price / Book Value ratio x3.02.1 145.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1353,746,408 0.5%   
No. of employees `0001.221.6 5.3%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.238,799.0 13.3%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.6-4,841.7 -14.4%   
INCOME DATA
Net Sales Rs m5,963838,058 0.7%  
Other income Rs m18-2,092 -0.9%   
Total revenues Rs m5,981835,966 0.7%   
Gross profit Rs m1,430107,660 1.3%  
Depreciation Rs m258181,470 0.1%   
Interest Rs m-2626,434 -0.1%   
Profit before tax Rs m1,216-102,335 -1.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-7,507 0.9%   
Tax Rs m342-5,261 -6.5%   
Profit after tax Rs m806-104,581 -0.8%  
Gross profit margin %24.012.8 186.7%  
Effective tax rate %28.15.1 547.3%   
Net profit margin %13.5-12.5 -108.3%  
BALANCE SHEET DATA
Current assets Rs m5,102441,549 1.2%   
Current liabilities Rs m2,385322,019 0.7%   
Net working cap to sales %45.614.3 319.4%  
Current ratio x2.11.4 156.0%  
Inventory Days Days15058 258.6%  
Debtors Days Days11366 170.9%  
Net fixed assets Rs m5,148102,335 5.0%   
Share capital Rs m1580-   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,7321,817,717 0.4%   
Long term debt Rs m952952,519 0.1%   
Total assets Rs m10,3883,331,277 0.3%  
Interest coverage x-45.8-2.9 1,594.3%   
Debt to equity ratio x0.10.5 27.0%  
Sales to assets ratio x0.60.3 228.2%   
Return on assets %7.5-2.3 -320.0%  
Return on equity %12.0-5.8 -208.1%  
Return on capital %14.6-3.0 -485.0%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274143,911 0.9%  
From Investments Rs m-1,204-344,578 0.3%  
From Financial Activity Rs m-196193,603 -0.1%  
Net Cashflow Rs m-126-7,064 1.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: ALEMBIC PHARMA  VENUS REMEDIES  PLETHICO PHARMA  AJANTA PHARMA  DIVIS LABORATORIES  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS